Clinical trial
A Safety Study in Patients With Chronic Lymphocytic Leukemia
NCT00283101 · Seagen Inc., Industry · Completed
Key facts
| NCT number | NCT00283101 |
|---|---|
| Title | A Safety Study in Patients With Chronic Lymphocytic Leukemia |
| Official title | A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia |
| Lead sponsor | Seagen Inc., Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Chronic |
| Intervention type | Drug |
| Interventions | SGN-40 (anti-huCD40 mAb) |
| Enrollment | 12 |
| Start date | Jul 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Jan 27, 2006 |
| Last update posted | Dec 18, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: